Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Figer

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Risk of colorectal neoplasia associated with the adenomatous polyposis coli E1317Q variantM J Hall, E Liberman, O Dulkart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyLeonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJim Cassidy, Josep Tabernero, Chris Twelves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2006
Phase II study of sorafenib in patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Lawrence Schwartz, Sergio Ricci, et al.
Lancet (London, England)|September 21, 2002
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised studyCornelis J A Punt, Attila Nagy, Jean-Yves Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 studyB Chibaudel, C Tournigand, P Artru, et al.
Clinical Colorectal Cancer|August 16, 2005
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II studyChris J Twelves, Charles A Butts, Jim Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR studyChristophe Tournigand, Andres Cervantes, Arie Figer, et al.
British Journal of Cancer|September 11, 2003
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trialC-H Köhne, R Catane, B Klein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Risk of colorectal neoplasia associated with the adenomatous polyposis coli E1317Q variantM J Hall, E Liberman, O Dulkart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyLeonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJim Cassidy, Josep Tabernero, Chris Twelves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2006
Phase II study of sorafenib in patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Lawrence Schwartz, Sergio Ricci, et al.
Lancet (London, England)|September 21, 2002
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised studyCornelis J A Punt, Attila Nagy, Jean-Yves Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 studyB Chibaudel, C Tournigand, P Artru, et al.
Clinical Colorectal Cancer|August 16, 2005
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II studyChris J Twelves, Charles A Butts, Jim Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR studyChristophe Tournigand, Andres Cervantes, Arie Figer, et al.
British Journal of Cancer|September 11, 2003
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trialC-H Köhne, R Catane, B Klein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Pageof 11